Lenalidomide Krka 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
IB/0006/G 
This was an application for a group of variations. 
08/06/2023 
17/07/2023 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0004 
C.I.3.z - Change(s) in the SPC, Labelling or PL 
15/12/2021 
18/07/2022 
SmPC, 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Other variation 
Labelling and 
PL 
IB/0003 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
11/10/2021 
18/07/2022 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
IAIN/0002 
A.2.a - Administrative change - Change in the 
04/08/2021 
18/07/2022 
SmPC, Annex 
(invented) name of the medicinal product for CAPs 
II, Labelling 
and PL 
IA/0001 
B.II.b.4.a - Change in the batch size (including batch 
07/05/2021 
n/a 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
Page 2/2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
